DSS Plans New Share Sale To Boost Working Capital

DSS, Inc. Announces SEC Declaration of Effectiveness of Form F-4 Registration Statement for Business Combination

DSS, Inc. announced that the SEC declared effective the Form F-4 registration statement for the proposed business combination involving its subsidiary, Impact Biomedical Inc., and Zoar Limited.

8-K filing — DSS, INC. (DSS)

Filed: 2026-09-21 AccNo: 0001493152-26-043561 Size: 650 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits

DSS Launches New Business, DSS Robotics, Focused On AI-Powered Robotics And Intelligent Automation Solutions For Enterprise Customers

DSS, Inc. (NYSE:DSS), a diversified technology company with experience in enterprise IT services, digital transformation, cybersecurity and authentication technologies, today announced the launch of DSS Robotics, a new

DSS shares are trading lower after the company announced it has decided not to proceed with its planned public offering due to limited shelf registration capacity.

DSS, Inc. Announces Decision Not to Proceed with Proposed Public Offering

DSS, Inc. announced on September 4, 2026, that it has decided not to proceed with its previously announced public offering of Common Stock due to limited capacity under its existing shelf registration statement. The company continues to explore alternative capital-raising options while remaining focused on shareholder value creation.

DSS Plans Not To Proceed With Previously Announced Common Stock Offering

DSS, Inc. (NYSE:DSS) (the "Company"), a multinational company operating across diverse industries including product packaging, biotechnology, commercial lending, and securities and investment management, today